Hims & Hers Health Balance Sheet Health
Financial Health criteria checks 6/6
Hims & Hers Health tiene unos fondos propios totales de $328.6M y una deuda total de $0.0, lo que sitúa su ratio deuda/fondos propios en 0%. Sus activos y pasivos totales son $413.9M y $85.3M respectivamente.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$220.98m |
| Equity | US$344.03m |
| Total liabilities | US$97.16m |
| Total assets | US$441.19m |
Recent financial health updates
Recent updates
Hims & Hers Health: Strong Prospects But Weak Business Model Consolidation
Apr 05Hims & Hers: 5 Reasons Why This Is A Phenomenal Long-Term Growth Stock
Mar 21Pills Pay The Bills: Mini Deep Dive On Hims & Hers Health
Mar 12Investors Appear Satisfied With Hims & Hers Health, Inc.'s (NYSE:HIMS) Prospects As Shares Rocket 49%
Feb 28
Hims & Hers: Turning The Profitability Corner And Returning 28%
Feb 25Hims & Hers Health: No Clear Moat Besides First Mover Advantage
Jan 23Hims & Hers Health: Unleashing Macro Momentum - Investing In Growth At A Higher Multiple
Jan 10Investors Still Waiting For A Pull Back In Hims & Hers Health, Inc. (NYSE:HIMS)
Jan 07Hims & Hers Health Q3: The Cheapest Growth Stock Around
Dec 14Hims & Hers Health: What Would The Author Of 100 Baggers Say?
Nov 30Hims & Hers: The Most Undervalued Small Cap Stock I See
Nov 08Hims & Hers: A Promising Company With Resolvable Challenges
Nov 02Hims & Hers: Specialization Is The Secret To Great Growth
Oct 25Hims & Hers Health: Can't Get Much Better
Sep 25The Market Is Wrong On Hims & Hers Health
Sep 18Hims & Hers: The Current Weakness Creates A Buying Opportunity
Aug 15Hims & Hers Health: Giving Investors Another Bite At The Apple
Aug 01Hims & Hers Health, Inc.'s (NYSE:HIMS) Price In Tune With Revenues
Jul 21Hims & Hers Health: Expect Strong EBITDA Growth As Revenue Growth Remains Strong
Jul 13Hims & Hers Health: Double-Edged Sword
Jul 02Hims & Hers: More Transparency Could Help The Stock
Jun 09Hims & Hers Health (NYSE:HIMS) Is In A Strong Position To Grow Its Business
Apr 19Are Investors Undervaluing Hims & Hers Health, Inc. (NYSE:HIMS) By 41%?
Mar 30Him & Hers Health Q4 2022 Earnings Preview
Feb 24Hims & Hers spikes as Jefferies upgrades ahead of 2023 guidance
Feb 09Hims & Hers: Profitability Pulled Forward
Jan 25Hims & Hers Health: Buy Into The Strong Growth Momentum
Jan 18Devon Energy And Hims & Hers Health - Raul Shah's Hot Take
Jan 05Hims & Hers Health: The Ultimate Pick For 2023
Dec 23Hims & Hers Health: The Unicorn (Former) SPAC For 2023
Dec 17Hims & Hers Health Seems Like A Great Pick For 2023
Dec 10Party Time: Brokers Just Made Major Increases To Their Hims & Hers Health, Inc. (NYSE:HIMS) Earnings Forecasts
Nov 12Financial Position Analysis
Pasivos a corto plazo: HIMSLos activos a corto plazo ($250.2M) de la empresa superan a sus pasivos a corto plazo ($82.5M).
Pasivo a largo plazo: HIMSLos activos a corto plazo ($250.2M) superan a sus pasivos a largo plazo ($2.8M).
Debt to Equity History and Analysis
Nivel de deuda: HIMS está libre de deudas.
Reducción de la deuda: HIMS no tiene deuda en comparación con hace 5 años, cuando su ratio deuda/fondos propios era de 36.9%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Cash runway estable: Aunque no es rentable HIMS tiene suficiente cash runway para más de 3 años si mantiene su actual nivel positivo de free cash flow.
Pronóstico de cash runway: HIMS no es rentable pero tiene suficiente liquidez para más de 3 años, debido a que el flujo de caja libre es positivo y crece un 38.4% al año.